Medicines that either have a questionable level of added benefit or are innovative products for which a substantial benefit is expected but where evidence uncertainties remain are the most likely to be met with requests for post-market data collection, according to a new study from the health technology assessment (HTA) department at France’s HAS (Haute Autorité de Santé).
The study was conducted with the intention of helping pharmaceutical companies to better plan their strategies for collecting real-world evidence (RWE) in a post-market setting
Key Takeaways
-
In France, post-market studies were most likely to be requested by the country’s HTA body for drugs where added benefit was uncertain, or for innovative products with evidence uncertainties.
-
Certain therapeutic areas, such as neurology, pulmonology and endocrinology, were also linked with higher numbers of post-market study requests